Wobbly Parexel International snapped up for $5B in latest CRO buyout
The big CRO shakeup continues this morning with news of Pamplona Capital’s $5 billion acquisition of Parexel International, one of the biggest players in the business.
Pamplona said this morning that it has forged a deal to acquire the contract research outfit for $88.10 a share. That’s 28% higher than the price of Parexel shares $PRXL on May 5, the day before the first market rumors of a buyout began to circulate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.